Astro-Med, Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Astro-Med, Inc. on November 24, 2014. The filing discloses the execution of new executive compensation agreements and employment contracts.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation arrangements.
Material Changes and Executive Agreements
On November 24, 2014, the Company entered into significant agreements with key executives:
- CEO Equity and Change in Control Agreement: Gregory A. Woods, CEO, received an Equity Incentive Award Agreement and a Change in Control (CIC) Agreement.
- Equity Grants: The Company will grant Mr. Woods options for 50,000 shares annually in 2015, 2016, and 2017. Additionally, restricted stock awards will be granted based on the difference between the option exercise price and $13.80 per share.
- Vesting: Awards vest in four equal annual installments or immediately upon a change in control.
- Change in Control Payout: If a change in control occurs before June 1, 2018, Mr. Woods is entitled to a cash payment equal to the positive difference between the fair market value and $13.80, multiplied by the number of ungranted options.
- Severance: Upon termination without cause within two years of a change in control, Mr. Woods receives 1.5x base compensation (salary + target/highest bonus), immediate vesting of all equity, 18 months of health coverage, and outplacement services. Payments are subject to "golden parachute" reduction rules under Section 280G.
- VP Employment Contract: The Compensation Committee approved an employment contract for Michael Morawetz, Vice President – International Branches.
- Compensation: Base salary set at €157,590, plus participation in the Management Bonus Plan and fringe benefits.
- Termination: The contract allows termination at the end of any quarter with six months' prior notice.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, outlook, or general risk factors. The primary contingency noted is the potential for "excess parachute payments" under Section 280G of the Internal Revenue Code, which would trigger a reduction in severance benefits to avoid excise taxes.
Investor Verification Checklist
- Verify the current fair market value of Astro-Med, Inc. common stock to assess the potential value of the restricted stock awards tied to the $13.80 threshold.
- Review the Company's capital structure for any pending stock splits or dividends that would adjust the 50,000 share option grants.
- Confirm the specific terms of the Management Bonus Plan applicable to Michael Morawetz to understand total potential compensation.
- Monitor for any future filings regarding a change in control, which would trigger immediate vesting and potential cash payouts to the CEO.